• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
The 'Press Releases' section offers the latest product-specific and company-related updates to our esteemed clients, providing them with a valuable resource. Members can leverage this platform for quick, efficient, and effective visibility.

— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
Walgreens

Walgreens provides no-cost rapid COVID-19 and flu testing for military veterans

To help improve access to fast, reliable testing for veterans, Walgreens is now offering no-cost testing through a partnership with the Centers for Disease Control and Prevention (CDC).* Eligible veterans will be able to receive an easy combination test for COVID-19 and influenza at Walgreens locations across the country throughout this year’s respiratory season, with results in 30 minutes or less.** No-cost COVID-19 and flu testing will also continue to be available at Walgreens for uninsured patients via the CDC program.

Read more →
DermaSensor

DermaSensor named in TIME's Best Inventions of 2024 list

DermaSensor, a world leader in skin cancer diagnostic technology, announced the company’s inclusion in TIME’s Best Inventions of 2024 list under the Medical Care category. TIME’s prestigious award recognizes 200 innovations that TIME editors deem as the most impactful new products and ideas globally.

Read more →
JYLAMVO™

Shorla Oncology gains FDA expanded approval for JYLAMVO™ (methotrexate) for pediatric oncology and autoimmune uses

Shorla Oncology a U.S.-Ireland specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of JYLAMVO™ (methotrexate) to include the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (pJIA). With this approval, JYLAMVO is currently the only oral liquid methotrexate on the market approved for both adult and pediatric indications.

Read more →
SirPlux™ Duo Drug-Coated Balloon (DCB)

Advanced Nanotherapies sees success in initial SIRPLUX™ Duo trial, eyes U.S. feasibility study

Advanced NanoTherapies (ANT), a clinical-stage medical device company committed to solving the most significant challenges in vascular disease through innovative applications of nanotechnology, announced positive results from its first-in-human (FIH) trial evaluating the next-generation SirPlux™ Duo Drug-Coated Balloon (DCB).

Read more →
Anixa Biosciences

Anixa Biosciences delivers second dose in ovarian cancer CAR-T trial

Anixa Biosciences, Inc. "Anixa" or the a biotechnology company focused on the treatment and prevention of cancer, announced that it has administered the second dose of its CAR-T therapy to an individual patient.This follows a positive response after the initial treatment in the ongoing Phase 1 clinical trial of its chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. The study is being conducted in collaboration with Moffitt Cancer Center.

Read more →
Regenity Biosciences

Regenity Biosciences gains 510(k) clearance for RejuvaKnee™, a regenerative meniscus implant

Regenity Biosciences, a global leader in regenerative medicine and Linden Capital Partners portfolio company, announced that it has received FDA 510(k) clearance to market RejuvaKnee™, a minimally invasive collagen-based meniscal implant indicated for use in the reinforcement and repair of soft tissue injuries of the meniscus.

Read more →
Chip-R1™ Rigid Chip

Emulate, Inc. introduces the Chip-R1™ Rigid Chip for improved biological modeling in ADME and toxicology applications

Emulate, Inc., the leading provider of next-generation in vitro Organ-Chip models, announced the release of its new Chip-R1™ Rigid Chip, designed to minimize drug absorption and enhance biological modeling. Constructed using low-drug-absorbing plastics, Chip-R1 builds upon the core microfluidic design of Organ-Chips, offering researchers greater precision in predicting human drug responses.

Read more →
Spineology®

Spineology® Announces Organization Rebrand

Spineology Inc., the pioneer of Conform and Expand™ Technology, unveiled a new brand and visual identity, logo, and product positioning as part of an extensive rebranding initiative. This new brand defines Spineology’s flagship interbody fusion portfolio, OptiMesh®, and establishes it within a category of its own.

Read more →